Copyright
©The Author(s) 2019.
World J Gastroenterol. Jan 14, 2019; 25(2): 163-177
Published online Jan 14, 2019. doi: 10.3748/wjg.v25.i2.163
Published online Jan 14, 2019. doi: 10.3748/wjg.v25.i2.163
Target | Agent | Action | Clinical trial |
Diabetes, insulin resistance | Semaglutide | DPP4 inhibitor | Phase II |
Gliflozin | SGLT2 inhibitor[89] | Pilot | |
BMS-986036 | Recombinant FGF21[90] | Phase II | |
Dyslipidemia | Aramchol | SCD inhibitor | Phase II |
GS-0976 | ACC inhibitor | Phase II | |
Nuclear receptor | Obeticholic acid | FXR agonist[84] | Phase III |
Elafibranor | PPARα/δ agonist[85] | Phase III | |
MGL-3196 | TRβ agonist | Phase II | |
Apoptosis | Emricasan | Pan-caspase inhibitor[91] | Phase II |
Inflammation, fibrosis | Selonsertib | ASK1 inhibitor[87] | Phase III |
Cenicriviroc | CCR2/5 antagonist[88] | Phase III | |
JKB-121 | TLR4 antagonist | Phase II | |
GR-MD-02 | Galectin 3 inhibitor[92] | Phase II | |
ND-LO2-s0201 | HSP47 siRNA[93] | Phase I |
- Citation: Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol 2019; 25(2): 163-177
- URL: https://www.wjgnet.com/1007-9327/full/v25/i2/163.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i2.163